Τόμος 22 (2008) – Τεύχος 2 – Άρθρο 80 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Article 80 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

A’ Department of Pharmacology, Medical School, Aristotle University, Thessaloniki, Greece

pharmakonpress[at]pharmakonpress[.]gr

2. Berrios G.E.: Alzheimer’s disease: A conceptual history. Int. J. Ger. Psychiatry 5: 355-365 (1990)

3. World Health Organisation (Webpage):

http://www.searo.who.int/en/Section1174/Section1199/Section1567/Section1823_8066.htm

4. St George-Hyslop P.H., Petit A.: Molecular biology and genetics of Alzheimer’s disease. Comptes Rendus Biologies 328: 119-130 (2005)

5. Bertram L., Tanzi R.E.: Alzheimer’s disease: one disorder, too many genes? Hum. Molec. Genetics 13(Spec No 1): R135-141 (2004)

6. Rubinsztein D.C.: The genetics of Alzheimer’s disease. Progr. Neurobiol. 52: 447-454 (1997)

7. Pastorino L., Lu K.P.: Pathogenic mechanisms in Alzheimer’s disease. Eur. J. Pharmacol. 545 (1): 29-38 (2006)

8. Hutton M., Hardy J.: The Presenilins and Alzheimer’s disease. Hum. Molecul. Genetics 6: 1639-1646 (1997)

9. St George-Hyslop: Role of genetics in tests of genotype, status and disease progression in early-onset Alzheimer’s disease. Neurobiol. Aging. 19: 133-137 (1998)

10. Tanzi R.E., Bertram L.: New frontiers in Alzheimer’s Disease genetics. Neuron 32:181-184 (2001)

11. Cacabelos R.: Pharmacogenomics in Alzheimer’s dis-ease. Mini Rev. Med. Chem. 2: 59-84 (2002)

12. Heneka M.T.: Inflammation in Alzheimer’s disease. Clin. Neuroscie. Res. 6: 247-260 (2006)

13. Stuchbury G., Munch G.: Alzheimer’s associated inflammation, potential drug targets and future therapy. J. Neural Transmission 112: 429-453 (2005)

14. Benseny-Cases N., Cocera M., Cladera J.: Conversion of non-fibrillar β-sheet oligomers into amyloid fibrils in Alzheimer’s Disease amyloid peptide aggregation. Biochem. Biophys. Res. Commun. 361: 916-921 (2007)

15. Findeis M.A.: The role of Aβ peptide 42 in Alzheimer’s disease. Pharmacol. Ther. 116: 266-286 (2007)

16. Rowan M.J., Klyubin I., Wang Q., Hu N.W., Anwyl R.: Synaptic memory mechanisms: Alzheimer’s Disease amyloid-beta peptide-induced disfunction. Biochem. Society Transactions 35(Pt 5): 1219-1223 (2007)

17. Selkoe D.J.: The cell biology of β-amyloid precursor protein and presenilins in Alzheimer’s disease. Trend Cell Biol. 8: 447-453 (1998)

18. Selkoe D.J.: Physiological production of the β-amyloid protein and the mechanisms of Alzheimer’s disease. TINS 16: 403-409 (1993)

19. Parvathy S., Hussain I., Karran E.H., Turner A.J., Hooper N.M.: Cleavage of Alzheimer’s amyloid precursor protein by alpha-secretase occurs at the surface of the neuronal cells. Biochemistry 38-30: 9728-9734 (1999)

20. Zigman W.B., Schupf N., Jenkins E.C., Urv T.K., Tycko B., Silverman W.: Cholesterol level, statin use and Alzheimer’s disease in adults with Down syndrome. Neurosci. Lett. 416: 279-84 (2007)

21. Sjögren M., Mielke M., Gustafson D., Zandi P., Skoog I.: Cholesterol and Alzheimer’s disease: is there a relation? Mech. Ageing Dev. 127: 138-47 (2006)

22. Shobab L., Hsiung G., Feldman H.: Cholesterol in Alzheimer’s disease. Lancet Neurol. 4: 841-852 (2005)

23. Casserly I., Topol E.: Convergence of atherosclerosis and Alzheimer’s disease: inflammation, cholesterol, and misfolded proteins. Lancet 363(9415): 1139-1146 (2004)

24. Zipp F., Waiczies S., Aktas O., Neuhaus O., Hemmer B., Schraven B., Nitsch R., Hartung H.-P. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol. Sci. 28: 342-349 (2007)

25. Panza F., D’Introno A., Colacicco A.-M., Capurso C., Pichichero G., Capurso S., Capurso A., Solfrizzi V.: Lipid metabolism in cognitive decline and dementia. Brain Res. Rev. 51: 275-292 (2006)

26. DeKosky S.: Statin therapy in the treatment of Alzheimer disease: what is the rationale? Am. J. Med. 118: 48-53 (2005)

27. Hartmann T.: Cholesterol, Aβ and Alzheimer’s disease. TINS 24(11): 45S-48S (2001)

28. Roensch J., Crisby M., Nordberg A., Xiao Y., Zhang L.-J., Guan Z.-Z.: Effects of statins on a7 nicotinic receptor, cholinesterase and a-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochem. Int. 50: 800-806 (2007)

29. Grimm M., Grimm H., Hartmann T.: Amyloid beta as a regulator of lipid homeostasis. Trends Molec. Med. 13: 337-344 (2007)

30. Standridge J.: Pharmacotherapeutic approaches to the prevention of Alzheimer’s Disease. Am. J. Geriatric Pharmacother. 2: 119-132 (2004)

31. Dominquez D., DeStrooper B.: Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer’s disease. Trends Pharmacol. Sci. 23: 324-330 (2002)

32. Cole S.L., Vassar R.: Isoprenoids and Alzheimer’s disease: A complex relationship. Neurobiol. Dis. 22: 209-222 (2006)

33. Tang B.: Alzheimer’s disease: Channeling APP to non-amyloidogenic processing. Biochem. Biophys. Res. Commun. 331: 375-378 (2005)

34. Jans D.M., Martinet W., Van De Parre T.J., Herman A.G., Bult H., Kockx M.M., De Meyer G.R.: Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer’s disease. Cardiovasc. Hematol. Disord. Drug Targets 6: 21-34 (2006)

35. Paris D., Townsend K., Humphrey J., Obregon D.F., Yokota K., Mullan M.: Statins inhibit Aβ-neurotoxicity in vitro and Aβ-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis 161: 293-299 (2002)

36. Sun Y.-H., Crisby M., Lindgren S., Jansciauskiene S.: Pravastatin inhibits pro-inflammatory effects of Alzheimer’s peptide Aβ(1–42) in glioma cell culture in vitro. Pharmacol. Res. 47: 119-126 (2003)

37. Ishii K., Tokuda T., Matsushima T., Miya F., Shoji S., Ikeda S., Tamaoka A.: Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans. Neurosci. Lett. 350: 161-164 (2003)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr